Compare AbbVie Inc (ABBV) vs Celestica Inc (CLS) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

Celestica (CLS) trades at $350.20, up 4.16% over 24 hours, with a bearish technical signal and neutral oscillators. The company shows strong fundamental momentum with three consecutive quarterly EPS beats and robust profitability metrics, including a 52.45% ROE. Recent leadership appointments in cloud solutions and positive analyst coverage highlight growth potential amid competitive pressures.

The stock presents a compelling growth opportunity with a consensus price target of $440.10, implying 25% upside, supported by AI and data center demand. Key risks include margin pressures, technical bearish signals, and reliance on execution amid industry competition. Investors should weigh strong earnings trajectory against near-term volatility.